|Day Low/High||51.93 / 53.26|
|52 Wk Low/High||46.94 / 70.05|
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter of 2018 on Thursday, January 24, 2019.
Bristol-Myers Squibb Company (NYSE: BMY) today announced it will transfer $3.8 billion of U.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that 19 data presentations and publications, including two oral presentations, from Company-sponsored studies and collaborations evaluating Opdivo (nivolumab), Sprycel (dasatinib) and Empliciti...
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Citi 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York.
Shares decline after the company says a lung-cancer study it had been working on failed.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Phase 3 CheckMate -451 study did not meet its primary endpoint of overall survival (OS) with Opdivo (nivolumab) 1 mg/kg in combination with Yervoy (ipilimumab) 3 mg/kg versus placebo as a...
Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that ReviveMed and Strand Therapeutics are the winners of Bristol-Myers...
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018, in Boston.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending approval of the Opdivo (nivolumab) plus low-dose Yervoy...
A split Congress is the best-case scenario for the drug industry, several analysts said.
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Credit Suisse Annual Health Care Conference on Wednesday, November 14, 2018 in Scottsdale, AZ.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S.
-- Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H'19 --
Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combination with Infinity's IPI-549 in patients with advanced urothelial...
Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
The Dow Jones Industrial Average snaps back solidly Thursday after plunging more than 600 points in the previous session.
Bristol-Myers Squibb posts stronger-than-expected third-quarter earnings Thursday and boosts its full-year profit outlook.
Global stocks were awash with red in overnight trading Thursday, loping billions in value from equity markets around Asia following last night's late-trading collapse on Wall Street which has erased year-to-date gains for benchmarks around the world amid concerns over weakening U.S. earnings growth, rising geo-political tensions and the unknown outcome of trade disputes between Washington and its major economic partners.
It becomes difficult for me to tell you where to run in these markets...
SAN DIEGO, Oct. 25, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2018 which were highlighted by strong sales and operating performance along with key regulatory and clinical milestones across the portfolio.
There is clear divergence between the best and the worst performers in each sector this earnings season.
Shares of Mirati Therapeutics fell Monday after the drug developer released a progress report of an early stage clinical trial of its lung cancer drug used in conjunction with a Bristol-Myers Squibb Co. medication.
Bristol-Myers Squibb fall sharply after the U.S. Food & Drug Administration extends the approval date for a combination-drug treatment for lung cancer patients.
Stocks are mixed after rising earlier in the session following a rally in China that saw stocks soar to their biggest single-day gain in nearly three years.
Bristol-Myers Squibb Company (NYSE:BMY) today announced the results of a new analysis from the Phase 3 CheckMate -214 study, demonstrating that therapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with previously untreated advanced or...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.